The Commonwealth Serum Laboratories (CSL) was sold in 1994 by the Commonwealth and became a privately owned company, tasked with the processing of blood. Since its privatisation it has been accused of allowing hepatitis-C and CJD to infect the blood. This document focuses on the $400 million given to CSL by the Commonwealth between 1994 and 1999, funding which had no oversight once given to CSL.